Investigation of the haemodynamic effects of exenatide in healthy male subjects.

Mendis B, Simpson E, MacDonald I, Mansell P

British journal of clinical pharmacology1 Sept 2012Cited by 50 (Europe PMC)

PMID22320349PMCIDPMC3477345DOI10.1111/j.1365-2125.2012.04214.xPepBankPUB-22320349

Summary

The text of this summary is not shown here, because the article license does not allow reuse. Read it at the source (opens in a new tab)

Text rights: Publisher copyright. Results still quote short attributed sentences.

Results from this study5

5 results from studies that gave the peptide. 5 results from people.

01HumanRandomized controlled trialEfficacy outcome
In healthy men, exenatide increased heart rate compared with placebo.
In plain wordsIn healthy men, exenatide increased heart rate compared with placebo.
Peptide
Exenatide (exendin-4)
Outcome
IncreaseHeart rate
Study
n: not reported in source
Comparator
Placebo
Outcome group
Heart function · Cardiovascular
Studied dose
10 µg · subcutaneous · 2 hAs given in this study (human).
Measurements
Heart rate difference
8.2 beats min(-1)
exenatide versus placebo
Source sentences
Summary
heart rate had risen by a mean of 8.2 (95% CI 4.2, 12.2, P < 0.01) beats min(-1)
2 context sentences(design, population, supporting numbers)
Summary · context
We have therefore studied the haemodynamic effects of exenatide in healthy male volunteers.
Summary · context
We compared the effects of a single 10 µg subcutaneous injection of exenatide with placebo in a double-blind, randomized, crossover study.
Report a problemFND-2232034901
02HumanRandomized controlled trialEfficacy outcome
In healthy men, exenatide increased cardiac output compared with placebo.
In plain wordsIn healthy men, exenatide increased the volume of blood pumped compared with placebo.
Peptide
Exenatide (exendin-4)
Outcome
IncreaseCardiac output
Study
n: not reported in source
Comparator
Placebo
Outcome group
Heart function · Cardiovascular
Studied dose
10 µg · subcutaneous · 2 hAs given in this study (human).
Measurements
Cardiac output difference
1.2 l min(-1)
exenatide versus placebo
Source sentences
Summary
cardiac output by a mean of 1.2 (95% CI 0.42, 20.3, P < 0.05) l min(-1)
2 context sentences(design, population, supporting numbers)
Summary · context
We have therefore studied the haemodynamic effects of exenatide in healthy male volunteers.
Summary · context
We compared the effects of a single 10 µg subcutaneous injection of exenatide with placebo in a double-blind, randomized, crossover study.
Report a problemFND-2232034902
03HumanRandomized controlled trialEfficacy outcome
In healthy men, exenatide reduced total peripheral resistance compared with placebo.
In plain wordsIn healthy men, exenatide reduced resistance to blood flow compared with placebo.
Peptide
Exenatide (exendin-4)
Outcome
DecreaseTotal peripheral resistance
Study
n: not reported in source
Comparator
Placebo
Outcome group
Heart function · Cardiovascular
Studied dose
10 µg · subcutaneous · 2 hAs given in this study (human).
Measurements
Total peripheral resistance difference
−120 dyn s cm(-5)
exenatide versus placebo
Source sentences
Summary
total peripheral resistance had fallen by 120 (95% CI -8, -233, P < 0.05) dyn s cm(-5)
2 context sentences(design, population, supporting numbers)
Summary · context
We have therefore studied the haemodynamic effects of exenatide in healthy male volunteers.
Summary · context
We compared the effects of a single 10 µg subcutaneous injection of exenatide with placebo in a double-blind, randomized, crossover study.
Report a problemFND-2232034903
04HumanRandomized controlled trialEfficacy outcome
In healthy men, blood pressure did not differ between exenatide and placebo.
In plain wordsIn healthy men, blood pressure did not differ between exenatide and placebo.
Peptide
Exenatide (exendin-4)
Outcome
No significant changeBlood pressure
Study
n: not reported in source
Comparator
Placebo
Outcome group
Blood pressure · Cardiovascular
Studied dose
10 µg · subcutaneous · 2 hAs given in this study (human).
Source sentences
Summary
There were no differences in blood pressure.
2 context sentences(design, population, supporting numbers)
Summary · context
We have therefore studied the haemodynamic effects of exenatide in healthy male volunteers.
Summary · context
We compared the effects of a single 10 µg subcutaneous injection of exenatide with placebo in a double-blind, randomized, crossover study.
Report a problemFND-2232034904
05HumanRandomized controlled trialEfficacy outcome
In healthy men, exenatide increased urinary sodium to creatinine ratio compared with placebo.
In plain wordsIn healthy men, exenatide increased the urine sodium to creatinine ratio compared with placebo.
Peptide
Exenatide (exendin-4)
Outcome
IncreaseUrinary sodium to creatinine ratio
Study
n: not reported in source
Comparator
Placebo
Outcome group
Kidney function · Kidney and urinary
Studied dose
10 µg · subcutaneous · 2 hAs given in this study (human).
Measurements
Urinary sodium to creatinine ratio difference
12.4 mmol mmol(-1)
exenatide versus placebo
Source sentences
Summary
The urinary sodium : creatinine ratio was increased by mean 12.4 (95% CI 4.6, 20.2, P < 0.05) mmol mmol(-1) when exenatide was compared with placebo.
2 context sentences(design, population, supporting numbers)
Summary · context
We have therefore studied the haemodynamic effects of exenatide in healthy male volunteers.
Summary · context
We compared the effects of a single 10 µg subcutaneous injection of exenatide with placebo in a double-blind, randomized, crossover study.
Report a problemFND-2232034905

AI wrote and checked these results. AI can make mistakes, so check important results against the source.

Registered trials1

Trials this study reports on, or that list this study as a reference. Registry data from ClinicalTrials.gov.

1 trial · 1 completed · source ClinicalTrials.gov (opens in a new tab)

CompletedNot applicableNCT01046721

Study Looking at Cardiovascular Effects of Exenatide, Its Blood Pressure Lowering Effect and Its Mechanisms

University of Nottinghamn = 8Sept 2009 to Dec 2012

Type 2 Diabetes

Trial page ClinicalTrials.govUpdated 6 Mar 2018

Version history

PepBank keeps every version of the data on this study. Status changes from Retraction Watch, Europe PMC and Crossref are listed with their source.

Version 2Current
22 Oct 2026, 02:26 UTC
Study results updated
Version 1
21 Oct 2026, 18:59 UTC
First added · source update from Europe PMC

Subjects

Terms as the source lists them.

PepBank is a research reference. Talk to a doctor before you use any peptide.